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DBackground: The St Jude Medical Epic heart valve (St Jude Medical, Inc, St Paul, Minn) is a tricomposite
glutaraldehyde-preserved porcine bioprosthesis. The St JudeMedical Biocor porcine bioprosthesis is the precur-
sor valve to the St JudeMedical Epic valve. The Epic valve is identical to the Biocor valve except that it is treated
with Linx AC ethanol-based calcium mitigation therapy.
Methods: The St Jude Medical Epic valve was implanted in 761 patients (mean age 73.9  9.2 years) between
2003 and 2006 in the US Food and Drug Administration regulatory study in 22 investigational centers. The
position distribution was 557 aortic valve replacements, 175 mitral valve replacements, and 29 double valve re-
placements. Concomitant coronary artery bypass grafting was performed in 50.8% of patients undergoing aortic
valve replacement and 36.6% of those undergoing mitral valve replacement.
Results: The early mortality was 3.6% in aortic and 2.3% in mitral valve replacement. The follow-up was
1675.5 patient-years with a mean of 2.2  1.2 years/patient. Late mortality was 5.2%/patient-year in aortic
and 6.6%/patient-year in mitral valve replacement. The late major thromboembolism rate was 0.98%/pa-
tient-year for aortic and 2.6%/patient-year for mitral valve replacement. There were 19 reoperations, including
2 for structural valve deterioration, 1 for thrombosis, 9 for nonstructural dysfunction, and 7 for prosthetic valve
endocarditis. The actuarial freedom from reoperation owing to structural valve deterioration for aortic valve re-
placement at 4 years for age 60 years or less was 93.3% 6.4%; for ages 61 to 70 years, 98.1% 1.9%; and for
older than 70 years, 100% (P¼ .0006>70 vs 60 years). There were no events of structural deterioration with
mitral valve replacement. The actuarial freedom from major thromboembolism for all patients at 4 years was
93.6%  1.0%. The 2 cases of structural valve deterioration occurred in aortic valves that became perforated
without calcification causing aortic regurgitation.
Conclusions: The performance of the St Jude Medical Epic porcine bioprosthesis is satisfactory at 4 years for
both aortic and mitral valve replacement. This study establishes the early clinical performance including dura-
bility of this porcine bioprosthesis. (J Thorac Cardiovasc Surg 2011;141:1449-54)Supplemental material is available online.The quest to establish a bioprosthesis for cardiac valve
replacement that is durable for 20 to 25 years continues.
There are current reports of 18- to 20-year valve durability
experience with porcine and pericardial bioprostheses.1-3
Of these, the St Jude Medical Biocor porcine bioprosthesis
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Abbreviations and Acronyms
AVR ¼ aortic valve replacement
LV ¼ left ventricular
MVR ¼ mitral valve replacement
SVD ¼ structural valve deterioration
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Dinvestigational centers in theUnited States and Canada. Since
Biocor was introduced in 1981, multiple investigative groups
have reported on extended experience in the past 4 years.1,4,5
Two reports onmitral replacement populations have identified
remarkable durability performance in patients averaging just
under 50 years of age.5,6 The durability performance of the
Epic aortic and mitral bioprostheses has been reported in
a large 5-year study in an elderly population over 75 years
of age.7
This study establishes the early performance in a prospec-
tive evaluation of a large patient population and affords the
opportunity for extended evaluation.
METHODS
This evaluation incorporated the methodology detailed in the ‘‘Guide-
lines for Reporting Morbidity and Mortality after Cardiac Valvular Opera-
tions (Valve Interventions)’’8,9 and the requirements of the US Food and
Drug Administration for an investigational device exemption study.
Where there was variance, especially with regard to the definition of
hemorrhage, only antithrombotic hemorrhage was reported in this study.
Anticoagulation management was at the discretion of the standards of
care of the respective institutions.
The bioprosthesis was implanted in 761 patients (women 43.9%, men
56.1%) from 2003 to 2006. The mean age of the population was 73.9 
9.2 years, with a range of 24 to 93 years. There were 557 aortic (AVR),
175 mitral (MVR), and 29 double valve replacements. Of the patients in
the AVR group, 34 were less than 60 years of age, 101 were between 61
to 70 years, and 422 were older than 70 years. In the MVR population,
17 were younger than 60 years, 47 were between 61 and 70 years, and
111 were older than 70 years. The patient characteristics of the AVR and
MVR populations are detailed in Table 1. The populations were distin-
guished for gender, left atrial enlargement, pulmonary hypertension, con-
gestive heart failure, cardiac arrhythmias, left ventricular (LV)
dysfunction, and mitral valve repair (P<.0001).
Previous surgery had been performed in 23.3% of AVR and 31.4% of
MVR patients. Concomitant coronary artery bypass grafting was con-
ducted in 50.8% of AVR and 36.6% of MVR patients. Concomitant atrial
fibrillation ablation was performed in 5.4% of AVR and 23.4% of MVR
patients; the procedures were performed with surgical, radiofrequency, or
cryotherapy ablation.
Principal investigators from 8 of the study centers were selected to report
on all data from the 22 investigational North American centers. The study
centers and respective study principal investigators are shown in
Appendix 1. These principal investigators were chosen on overall implant
populationof thevarious centers. The enrolment in the study closed inMarch
2006. The follow-up incorporated 1675.5 patient-yearswith amean of 2.2
1.2 years per patient. The completeness of follow-up was 97.2% at 2 years
and 94.9% at 4 years forAVR and 96.6% at 2 years and 94.8% at 4 years for
MVR. The echocardiographic evaluation was complete for AVR at 6
months, 1 year, and 2 years in 93.4%, 93.5%, and 89.1% of the patients,
and for MVR at 6 months, 1 year, and 2 years in 91.4%, 94.2%, and
89.7% of the patients. The follow-upwas conducted at the investigating cen-1450 The Journal of Thoracic and Cardiovascular Surters by clinic evaluation, primary physician assessment or, if necessary, tele-
phone interviews and attainment of appropriate documentation. The follow-
up occurred at 6months, 1 year, and annually. The evaluation included echo-
cardiograms and blood assessment (inclusive of haptoglobin and serum lac-
tate dehydrogenase), as well as New York Heart Association functional
classification, medications, and documentation of any adverse events.
The statistical analyses were performed with SAS software (version
9.1.3; SAS Institute, Inc, Cary, NC). Descriptive summaries are expressed
as mean values for continuous variables and as percentage for categorical
variables; P values are from 2-sample t test or c2 test as appropriate.
Late adverse event rates (percent per patient-year) are expressed as a line-
arized rate ([the number of late events occurring 31 or more days after im-
plant/total late patient-years calculated for each subject from 31 days after
implant to the last contact] $ 100). Kaplan–Meier analyses are performed
for survival or freedom from the event rates, and groups are compared using
the log–rank static. Only Kaplan–Meier actuarial data analysis was re-
ported because of the objective to report on prosthesis performance and
not performance in a specific population subset (cumulative incidence,
actual analysis).
RESULTS
Theearlymortality (30-daymortality)was3.6% (20events)
for AVR and 2.3% (4 events) forMVR. The occurrence of the
predominant valve-related complications presented as linear-
ized occurrence rates (percent per patient-year) and actuarial
freedom at 4 years for both AVR and MVR populations
are detailed in Table 2 with the corresponding events. The
valve-related mortality for AVR was 0.4%/patient-year
and forMVR it was 1.1%/patient-year. Themajor thrombo-
embolism rates, inclusive of major cerebrovascular accident
and reversible ischemic neurologic deficit, were 0.98%/pa-
tient-year (12 events) and 2.6%/patient-year (9 events),
respectively, for AVR andMVR. The antithrombotic hemor-
rhage rates were 1.3%/patient-year (16 events) for AVR and
1.7%/patient-year (6 events) for MVR.
There were 9 late valve-related deaths occurring between
83 and 1080 days after implantation (prosthetic valve
endocarditis ¼ 2; periprosthetic leak ¼ 1; hemorrhage ¼ 2;
and sudden unexplained/unexpected ¼ 4). There was only
1 reoperation (prosthetic valve endocarditis); the patient
died during the reoperation for double valve replacement.
There were 21 cases of cerebrovascular accident/reversible
ischemic neurologic deficit (AVR¼ 12 andMVR¼ 9). Eight
patients had documented accompanying atrial fibrillation.
There were 2 cases of MVR thrombosis, only 1 requiring re-
operation. The additional case was managed conservatively
with anticoagulation.
Table 3 documents the actuarial performance of reopera-
tion of the overall events, as well as the events in each valve-
related complication category. There were 21 overall
reoperative events including 1 heart transplantation and 1
early reoperation for atrioventricular groove disruption.
All patients had successful surgery. Two patients required
reoperation for structural valve deterioration (SVD). Both
had had AVR, aged 47 and 61 years at implant, with the
finding of perforation(s) not associated with calcification
and presented with aortic regurgitation.gery c June 2011
TABLE 1. Patient population and medical history*
Variables AVR (n ¼ 557) MVR (n ¼ 175) P value
Age (y) 74.4  9.3 (24.6,93.3) 72.2  8.9 (44.5,91.4) .0054
Gender (male) 61.0% (340) 44.0% (77) <.0001
NYHA III/IV 55.5% (309) 61.7% (108) .1459
Systemic hypertension 76.5% (426) 69.1% (121) .0513
Left atrial enlargement 23.9% (133) 42.9% (75) <.0001
Diabetes mellitus 26.2% (146) 20.0% (35) .0966
TIA 6.3% (35) 3.4% (6) .1519
Stroke/RIND/CVA 6.6% (37) 6.9% (12) .9211
Pulmonary hypertension 14.2% (79) 34.9% (61) <.0001
Myocardial infarction 13.1% (73) 16.6% (29) .2482
Congestive heart failure 36.3% (202) 57.1% (100) <.0001
Hyperlipidemia 59.8% (333) 45.7% (80) .0011
Cancer 19.9% (111) 19.4% (34) .8850
Lung disease 21.2% (118) 18.3% (32) .4072
Coronary artery disease 65.0% (362) 49.7% (87) .0003
Carotid artery disease 12.7% (71) 6.9% (12) .0321
Peripheral vascular disease 14.0% (78) 7.4% (13) .0215
Endocarditis 1.4% (8) 2.9% (5) .2144
Cardiac arrhythmias 26.0% (145) 46.9% (82) <.0001
Renal failure 3.8% (21) 4.0% (7) .8900
LV dysfunction 66.8% (372) 46.9% (82) <.0001
RV dysfunction 0.5% (3) 2.3% (4) .0383
AV repair or replacement 0.9% (5) 0.0% (0) .2085
MV repair 0.2% (1) 7.4% (13) <.0001
Previous CABG 8.1% (45) 6.3% (11) .4362
Previous carotid endarterectomy 4.3% (24) 2.9% (5) .3905
Previous pacemaker 6.1% (34) 6.9% (12) .7203
Balloon annuloplasty 2.7% (15) 2.3% (4) .7675
Other surgery 7.5% (42) 16.0% (28) .0009
Valve dysfunction
Insufficiency 9.7% (54) 69.1% (121) <.0001
Stenosis 62.7% (349) 8.6% (15) <.0001
Mixed 27.6% (154) 21.7% (38) .1196
Not reported 0.0% (0) 0.6% (1) .2391
AVR, Aortic valve replacement;MVR, mitral valve replacement; NYHA, New York Heart Association; TIA, transient ischemic attack; RIND, reversible ischemic neurologic def-
icit;CVA, cerebrovascular accident; LV, left ventricular; RV, right ventricular; AV, aortic valve;MV,mitral valve;CABG, coronary artery bypass grafting. *A subject can be counted
in multiple categories based on his or her individual medical history.
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DThe pathologic evaluation of the 2 cases of SVD has iden-
tified abnormal findings of the native porcine leaflets, re-
sulting in perforations and tears:
The examining pathologist in the initial case concluded
that 2 of the cusps showed deterioration of the cuspal colla-
gen and increasing permeability of the cusps with fibrin per-
meation resulting in cuspal perforation. One of the cuspsTABLE 2. Valve-related late complications
AVR
Late complications,
%/pt-y (n)
KM freed
the event
Valve-related mortality 0.4 (5) 98.7%
Major TE (CVAþRIND) 0.98 (12) 94.5%
Thrombosis 0.0 (0) 100%
AVR, Aortic valve replacement; MVR, mitral valve replacement; KM, Kaplan–Meier; TE, t
logic deficit. *One subject had echocardiographic evidence of possible small thrombosis t
The Journal of Thoracic and Carhad an accompanying tear. The third cusp had focal areas
of thinning of the cuspal fibrosa. There was no evidence
of endocarditis or calcification.
The examining pathologist in the second case found that
all 3 leaflets contained attenuation of the fibrosa and fibrin
permeation of the spongiosa. Two leaflets had small perfo-
rations identical to each other near the free edges and theMVR
om from
,% at 4 y
Late complications,
%/pt-y (n)
KM freedom from
the event,% at 4 y
 0.6% 1.1 (4) 96.6%  1.5%
 1.2% 2.6 (9) 91.0%  2.5%
 0.0% 0.6 (2*) 97.9%  1.6%
hromboembolism; CVA, cerebrovascular accident; RIND, reversible ischemic neuro-
hat resolved on anticoagulant management.
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TABLE 3. Summary of freedom from reoperation for valve-related
complications
Reoperation Freedom Events
Overall 92.3%  2.3% 21*
Valve related 92.6%  2.3% 19
SVD 99.4%  0.4% 2
NSD 97.2%  1.4% 9 (PPL 6)
PVE 96.2%  1.9% 7
Thrombosis 99.7%  0.3% 1
SVD, Structural valve deterioration; NSD, nonstructural dysfunction; PPL, peripros-
thetic leak; PVE, prosthetic valve endocarditis. *Heart transplantation, n ¼ 1; atrio-
ventricular disruption, n ¼ 1.
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Dother leaflet had a linear tear. There was no evidence of
endocarditis or calcification.
Prosthetic valve endocarditis requiring reoperation
occurred in 7 cases. One case of mitral valve thrombosis
required reoperation in a patient with a history of endocar-
ditis. The remainder of events were due to nonstructural
dysfunction including 2 cases of pannus, 6 cases of para-
valvular leaks, and 1 case of dehiscence of the aortomitral
annular continuity requiring surgical repair.
The overall survival of the total population was 76.0%
2.7% at 4 years. Figures E1 and E2 illustrate survival by age
groups (group A  60, group B 61–70, and group C>70
years) for the AVR and MVR populations. For AVR,
survival for group B (61–70 years) was greater than for
group C (>70 years) (P ¼ .013), and survival for group A
(60 years) was greater than for group C (>70 years)
(P ¼ .011). There was no significant difference between
groups A and B (<60 years and 61–70 years; P ¼ .076).
Survival after MVR was not different by age groups
(P ¼ .145), but the patient populations were small for the
younger groups.
The actuarial freedom from valve-related mortality for
the overall population was 98.1%  0.6% at 4 years and
for all-cause reoperation, 92.3%  2.3% at 4 years
(Table 3). The actuarial freedom from valve-related reoper-
ation was 92.6%  2.3% at 4 years (Table 3).
The actuarial freedom from reoperation owing to SVD
for the overall population at 4 years was 99.4%  0.4%
(Table 3); for AVR 99.2%  0.6% and for MVR 100%.
The actuarial freedom from reoperation owing to SVD for
AVR age groups is illustrated in Figure 1. The freedom at
4 years for group A (60 years) was 93.3%  6.4%; for
group B (61–70 years), 98.1%  1.9%; and for group C
(>70 years), 100%. The actuarial freedom from reoperation
owing to SVD for MVR age groups is presented in Figure 2.
The freedom for each of the age groups (overall MVR range
44–91) is 100% at 4 years.
The actuarial freedom from overall thromboembolism at
4 years was 90.0%  1.7%. The freedom from major
thromboembolism and reversible ischemic neurologic defi-
cit at 4 years was 93.6% 1.0%. The freedom from antith-
rombotic hemorrhage at 4 years was 90.7%  1.2% and1452 The Journal of Thoracic and Cardiovascular Surfrom thrombosis, 99.6% 0.3%. (The freedom from reop-
eration owing to thrombosis was 99.7%  0.3%.)
The actuarial freedom from overall reoperation for pros-
thetic valve endocarditis at 4 years was 96.2%  1.9%
(Table 3). For the same time interval, the actuarial freedom
from reoperation owing to nonstructural dysfunction, inclu-
sive of periprosthetic leak, was 97.2%  1.4% (Table 3).
The hemodynamic performance at 6 months and 2 years
for AVR and MVR is illustrated in Figures E3 and E4. The
size distributions for AVR were as follows: 21 mm, 17.2%;
23 mm, 37.0%; 25 mm, 33.8%; 27 mm, 10.2%; and
29 mm, 1.7%. For the mitral valve they were as follows:
25 mm, 4.4%; 27 mm, 20.1%; 29 mm, 38.7%; 31 mm,
21.1%; and 33 mm, 15.7%. The mean gradients and
effective orifice areas for both positions are documented.
There was no occurrence greater than mild insufficiency
observed for the reoperation subjects, and prosthesis
insufficiency was not found to be an issue for these subjects.gery c June 2011
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DA total of 334 subjects with AVR had complete time
points (discharge, 6 month, 1 year, and 2 year). LV mass in-
dex data were available for the analysis. Themean (average)
LV mass index was reduced by 23.9 g/m2 (P<.001) from
discharge to 6months, 26.8 g/m2 (P¼ .0001) fromdischarge
to 1 year, and 27.6 g/m2 (P ¼ .0001) from discharge to
2 years (Figure E5).
DISCUSSION
The St Jude Medical porcine bioprostheses have been
evaluated in 5 publications since 2000.1,4-7 The Biocor
bioprosthesis was introduced in Brazil in 1981 and
performance over 20 years has been documented in 4 of
these publications. St Jude Medical markets the Biocor
porcine bioprosthesis worldwide. Biocor and Epic are the
same bioprostheses except that Biocor is formulated with no
calcium mitigation therapy whereas Epic is treated with
Linx AC, an ethanol-based therapy for calcium mitigation.
Both valves are tricomposite porcine bioprostheses with glu-
taraldehyde preservation at low-pressure conditions of less
than1mmHg.Midtermresults of theEpic bioprosthesis aortic
and mitral performance have been reported in 1 large series.7
The Biocor bioprosthesis has been reported by Myke´n
and Bech-Hansen1 in an AVR population of 70.8 years of
age and an MVR population of 64.9 years. Eichinger and
colleagues4 documented AVR performance in patients
with a mean age of 72.5 years. Kirali,6 Pomerantzeff,5
and their coinvestigators documented MVR performance
in populations with mean ages of 48 and 49.2 years, respec-
tively. The reported experience on the Biocor and Epic pros-
theses have concentrated on freedom from valve-related
mortality and freedom from SVD. They address durability
of SVD primarily by explant reoperation. There are no com-
ments on modes of failure in the reports on the Biocor bio-
prosthesis.
Before 2009, Myke´n and colleagues reported on the Bio-
cor bioprosthesis in 1994, 1995, 2000, and 2005. The recent
report (2009) documented the 20-year performance of the
Biocor valve in 1712 patients with 99.9% follow-up,
mean follow-up of 6.0 years for AVR and 6.2 years for
MVR.1 The 20-year freedom from actuarial valve-related
mortality was 84.3% for AVR and 88.0% forMVR. The ac-
tual/cumulative incidence of freedom from valve-related
mortality was 92.5% for AVR and 92.8% for MVR. The
20-year freedom from reoperative SVD in AVR (1518 pa-
tients) was 61.1% (actual 85.6%) and for MVR (194 pa-
tients), 79.3% (actual 91.2%). The actuarial freedom in
those older than 65 years and those 65 years or less for
AVR was 92.1% and 44.5%, respectively, and for MVR,
88.0% and 75.2%, respectively. There were 77 subjects
with SVD in the AVR by reoperative explant and 11 in
the MVR group, for an overall rate of 0.9%/patient-year.
The authors considered the durability of AVR and MVR
to be comparable.The Journal of Thoracic and CarIn 2008, Eichinger and coauthors4 reported on a cohort of
455 patients in whom the actuarial freedom from reopera-
tive SVD after AVR was 86.5% at 20 years (mean of 8.2
years, completeness of 99.6%). Three other reports had
documented 20-year experience with aortic porcine and
pericardial bioprostheses, but none of these publications
has adequate numbers at risk beyond 15 to 18 years to pro-
vide adequate assessment of 20-year durability.2,10,11
The MVR durability, reported by Pomerantzeff and col-
leagues5 in 2006, in 546 patients (mean age 48 years) at
15 years was 51.8% for those younger than 50 years,
88.7% for those 51 to 60 years, and 84.0% for those 61
to 80 years for reoperative SVD. The freedom from valve-
related mortality at 15 years was 80.7%. Kirali and coinves-
tigators6 documented performance in 2001 for 158 patients.
There were 39 SVD cases and 16 came to reoperation. The
overall freedom from SVD at 13 years was 64.8% and for
SVD reoperation, 76.8%. The authors reported the 15-
year freedom from valve-related mortality to be 98.6%.
The performance of 1168 AVR and 101 MVR Epic
valves implanted between 2001 and 2006, mean age of 76
years, provided 5-year satisfactory results.7 In this report
by Lehmann et al,7 the authors recommended long-term
evaluation of the calcium-mitigation therapy.
In this current Epic study, we report on the regulatory
population of 761 patients at 4 years: there were 2 AVR
SVD cases of aortic insufficiency owing to cuspal perfora-
tions and actuarial freedom from reoperation owing to SVD
for AVR at 4 years for ages 60 years and younger at
93.3%  6.4%; for ages 61 to 70 years at 98.1% 
1.9%; and for older than 70 years at 100% (P ¼ .0006>
70 vs  60 years). There were no cases of MVR SVD.
The mean follow-up was 2.2 years. The AVR SVD cases oc-
curred in patients aged 47 and 61 years.
Hemodynamic performancewas satisfactory for bothMVR
and AVR. All valves used were standard Epic aortic valves.
The newer Epic Supra aortic valve is designed for supra-
annular implantation and provides the potential for improved
hemodynamic performance. For the same tissue annulus di-
ameter, theEpicSupra incorporates a larger stent and therefore
has a larger stent/annulus ratio than does the Epic aortic. Re-
gardless, in the current study, LVmass regression significantly
improved in patients with sufficient follow-up data.
This study can serve as the basis for long-term durability
and performance evaluation of the St Jude Medical Epic
porcine bioprosthesis in both the aortic and mitral positions.
This will be important to confirm the favorable durability
considerations specifically for the mitral bioprosthesis.
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FIGURE E5. Left ventricular (LV) mass regression.
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